Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis

CONCLUSIONS: In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.PROTOCOL REGISTRATION: PROSPERO: CRD42022315577.PMID:38515177 | DOI:10.1186/s42358-024-00361-3
Source: Adv Data - Category: Epidemiology Authors: Source Type: research